1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026 RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-15 reverse stock split (the “Reverse Stock…
One year of work focused on one goal: manufacturing clinical material to enable once-weekly dosing RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company’s lead development…
RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed collaboration expands Lōkahi’s growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked,…
RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (Nasdaq: GCTK) today announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has confirmed that Glucotrack has regained compliance with Nasdaq’s stockholders’ equity requirement. The decision represents an important milestone…
Includes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium to the market, and $3.5 Million Follow-On Investment from Institutional Investors RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a…
Futures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 12 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry investment. RUTHERFORD, N.J. & LA JOLLA, Calif. – Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned…
FDA Type C Meeting and Nonclinical Study Advance Strategy to Transition LT-100 from 15 Injections to One RUTHERFORD, N.J. & LA JOLLA, Calif. – Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to…
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform RUTHERFORD, N.J. and LA JOLLA, Calif., July 16, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a…
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a…
RUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application titled…